Checkmate Pharmaceuticals, Inc.
NASDAQ: CMPI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Barry A. Labinger
- Employees
- 30
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Website
- https://www.checkmatepharma.com
Loading CMPI…
Loading profile data…Frequently asked questions about CMPI
What does Checkmate Pharmaceuticals, Inc. (CMPI) do?
Checkmate Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development of innovative cancer treatments. Its primary therapeutic candidate, CMP-001, is undergoing Phase II clinical trials. This investigational drug is being evaluated in combination with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors,...
Where does CMPI trade?
Checkmate Pharmaceuticals, Inc. (CMPI) trades on the NASDAQ Global Market.
What sector is CMPI in?
Checkmate Pharmaceuticals, Inc. (CMPI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Checkmate Pharmaceuticals, Inc.?
Barry A. Labinger is the chief executive officer of Checkmate Pharmaceuticals, Inc. (CMPI).
Where is Checkmate Pharmaceuticals, Inc. headquartered?
Checkmate Pharmaceuticals, Inc. is headquartered in United States.
Does CMPI pay a dividend?
Checkmate Pharmaceuticals, Inc. (CMPI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CMPI go public?
Checkmate Pharmaceuticals, Inc. (CMPI) completed its initial public offering in 2020.